GT Biopharma
GTBP
20 hedge funds and large institutions have $220K invested in GT Biopharma in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
11% more funds holding
Funds holding: 18 → 20 (+2)
51.9% less ownership
Funds ownership: 55.82% → 3.92% (-52%)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
99% less capital invested
Capital invested by funds: $29.3M → $220K (-$29.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$47.4K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$19.3K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$143 |
| 4 |
GIA
GHP Investment Advisors
Denver,
Colorado
|
+$78 |
| 5 |
FRA
Front Row Advisors
Tiburon,
California
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$29M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$33.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5.73K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.7K |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
-$19 |
GTBP Hedge Fund Activity: Q1 2025 in Review
20 of the 7,463 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q1 2025, worth a combined $220K — down 99% from $29.3M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new GTBP positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $47.4K. The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $29M sold.
- 20 institutional investors held GT Biopharma (GTBP) as of Q1 2025, up from 18 in Q4 2024.
- Funds reported $220K of GT Biopharma stock for Q1 2025, down 99% quarter-over-quarter.
- 3 funds opened new GT Biopharma positions in Q1 2025 and 1 closed out, a net change of +2 holders.
- The largest GT Biopharma buyer in Q1 2025 was Citadel Advisors, an estimated $47.4K added.
- The largest GT Biopharma seller in Q1 2025 was DekaBank Deutsche Girozentrale, an estimated $29M sold.
Based on aggregated 13F filings for Q1 2025.